CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本综述旨在系统总结 GPRC5D 靶向治疗多发性骨髓瘤的当前进展，从而为未来研究提供有价值的见解和基础。
作为一种快速发展的治疗方法，靶向治疗在多发性骨髓瘤的治疗中发挥着重要作用。近年来，针对成熟B细胞抗原的治疗为难治/复发患者带来了新的希望。随着越来越多的复发患者接触此类药物，改变治疗靶点可能是复发/难治多发性骨髓瘤患者的有效策略。
G蛋白偶联受体C类第5组成员D（GPRC5D）在骨髓瘤肿瘤细胞表面的表达使其成为复发/难治性多发性骨髓瘤治疗的潜在靶点，相关研究正在进行中。结果与
As a rapidly developing therapeutic method, targeted therapy plays an important role in the treatment of multiple myeloma. In recent years, mature B cell antigen-targeting therapy has brought new hope for patients with refractory/relapsed disease. While an increasing number of patients with relapse are exposed to this type of drug, changing the therapeutic target may be an effective strategy for patients with relapse/refractory multiple myeloma.
The expression of G protein-coupled receptor, class C Group 5 member D (GPRC5D), on the surface of myeloma tumor cells makes it a possible target for relapse/refractory multiple myeloma therapy, and relevant studies are in progress. RESULTS &
The review aims to systematically summarize the current advancements in GPRC5D-targeted therapies for multiple myeloma, thereby providing valuable insights and a foundation for future studies.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
